Entrada Therapeutics, Inc. Stock Price, News & Analysis

Entrada Therapeutics (Nasdaq: TRDA) will present at two investor conferences in late 2025. The company said CEO Dipal Doshi will deliver a presentation at the Jefferies Global Healthcare Conference in London on November 18, 2025 at 5:00 p.m. GMT and will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on December 3, 2025 at 12:55 p.m. ET.

Both events will be webcast live via the company’s Investor Relations website at www.entradatx.com, with replays available for 90 days after each event.

Entrada Therapeutics (Nasdaq: TRDA) has announced the recipients of its third annual DREAMS Grant Program, awarding $50,000 each to two non-profit organizations: Jett Foundation (US) and Parent Project aps (Italy). The grants aim to support underrepresented and underserved members of the Duchenne muscular dystrophy community.

Jett Foundation will utilize the funding for its Camp Promise program, targeting individuals aged 18 and older with Duchenne and other neuromuscular disorders, aiming to support over 250 campers in 2025. Parent Project aps will focus on providing home-based care and teleconsultation services to families in underserved regions of Southern Italy.

The recipients were selected by an independent grant review committee comprising neuromuscular leaders and advocates, with the announcement made ahead of World Duchenne Awareness Day on September 7.

Entrada Therapeutics (Nasdaq: TRDA) announced the granting of equity incentives to seven new non-executive employees under its 2025 Inducement Equity Plan. The grants include 54,360 restricted stock units (RSUs) and options to purchase 38,850 shares at an exercise price of $5.47 per share.

The options will vest over four years, with 25% vesting after one year and the remaining 75% vesting monthly over three years. The RSUs will vest 25% after one year, followed by quarterly vesting of 6.25% on specified dates. All grants are subject to continued employment and were approved as material inducements under Nasdaq Listing Rule 5635(c)(4).

Entrada Therapeutics (Nasdaq: TRDA) reported Q2 2025 financial results and clinical progress. The company achieved significant milestones in its Duchenne muscular dystrophy (DMD) programs, with the first patient dosed in ELEVATE-44-201 and initiation of ELEVATE-45-201. Financial highlights include $354 million in cash providing runway into Q2 2027, though the company reported a net loss of $43.1 million compared to $55.0 million net income in Q2 2024.

The company strengthened its leadership team with key appointments and advanced multiple clinical programs across the UK, EU, and US. Data from the first patient cohort of ELEVATE-44-201 is expected in H1 2026, while ELEVATE-45-201 is set to dose its first patient in Q3 2025. Entrada also plans regulatory submissions for ELEVATE-50 in Q4 2025 and ELEVATE-51 in 2026.

Entrada Therapeutics (NASDAQ: TRDA) has appointed Dr. Maha Radhakrishnan to its Board of Directors. Dr. Radhakrishnan currently serves as Executive Partner at Sofinnova Investments, bringing extensive experience in global drug development. She previously held the position of Group SVP and Chief Medical Officer at Biogen and served in leadership roles at Sanofi, Bioverativ, Bristol Myers Squibb, UnitedHealth Group, and Cephalon. The appointment comes as Entrada advances its Duchenne muscular dystrophy franchise, with promising Phase 1 safety and target engagement data. The company aims to develop intracellular therapies for Duchenne and other serious diseases, with multiple patient-focused clinical trials planned throughout the year.

Entrada Therapeutics (NASDAQ: TRDA) has granted 23,820 restricted stock units (RSUs) to six new non-executive employees under its 2025 Inducement Equity Plan, effective June 1, 2025. The grants were approved by the Board's Compensation Committee as a material inducement for employment, complying with Nasdaq Rule 5635(c)(4). The vesting schedule includes 25% vesting after one year, followed by quarterly vesting of 6.25% on March 1, June 1, September 1, and December 1 of subsequent years, contingent on continued employment. The RSUs are governed by the Inducement Plan terms approved in March 2025 and individual award agreements.

Entrada Therapeutics (NASDAQ: TRDA) has received EU authorization to begin ELEVATE-45-201, a Phase 1/2 multiple ascending dose clinical study for ENTR-601-45 in patients with Duchenne muscular dystrophy (DMD) amenable to exon 45 skipping. The study, set to begin in Q3 2025, follows recent UK authorization and will be conducted in two parts. Part A will evaluate safety and pharmacodynamics in approximately 24 patients across three cohorts, with doses ranging from 5 mg/kg to 15 mg/kg administered every six weeks. Part B will assess the optimal dose for safety and efficacy. The study represents the most advanced clinical trial of a conjugated exon skipping therapy for exon 45 skipping-amenable patients.

Entrada Therapeutics (TRDA) reported Q1 2025 financial results and key business updates. The company received EU regulatory authorization for ELEVATE-44-201, a Phase 1/2 MAD clinical study for ENTR-601-44 in Duchenne muscular dystrophy patients. Entrada maintains a strong financial position with $382.5 million in cash as of March 31, 2025, expecting runway into Q2 2027. Q1 financial results showed collaboration revenue of $20.6M (vs $59.1M in Q1 2024), R&D expenses of $32.1M (vs $28.6M), and a net loss of $17.3M (vs $23.5M net income). The company implemented a strategic plan focusing on DMD clinical candidates, reducing workforce by 20%. Three DMD programs (exon 44, 45, and 50 skip) are expected to enter clinical development by year-end, while partner Vertex continues progressing VX-670 for myotonic dystrophy type 1.

Entrada Therapeutics (NASDAQ: TRDA) has received authorization from the UK's MHRA to initiate ELEVATE-45-201, a Phase 1/2 multiple ascending dose clinical study for ENTR-601-45 in Duchenne muscular dystrophy (DMD) patients amenable to exon 45 skipping.

The study is structured in two parts: Part A will evaluate safety, pharmacokinetics, and pharmacodynamics in approximately 24 patients across three cohorts, with doses ranging from 5 mg/kg to 15 mg/kg administered every six weeks. Part B will further assess the optimal dose established in Part A. Study participants may be eligible for an open-label extension study.

The company plans to initiate the study in Q3 2025. ELEVATE-45 represents the second of three Duchenne programs Entrada expects to advance into global clinical development in 2025, with regulatory filings already submitted in the EU.